鶹Ƶ’s Deep Genomics secures $40 million in financing for AI drug development platform: Betakit
Published: January 10, 2020
Deep Genomics, an artificial intelligence-powered drug discovery start-up co-founded by the University of Toronto’s Brendan Frey, recently raised $40 million in Series B funding, .
The latest round, led by Future Ventures and including investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures, brings the startup’s total funding to date to $61 million.
Betakit notes that Deep Genomics in September “identified a new treatment target and corresponding drug candidate for Wilson disease,” a rare genetic disorder that causes an accumulation of copper in vital organs, which can be fatal if left untreated.
The capital will help Deep Genomics, , bring its Wilson disease program to the clinic, said Frey, a founding member of the Vector Institute for Artificial Intelligence and a professor in the department of electrical and computer engineering in the Faculty of Applied Science & Engineering.
Topics
